Treatment of Paget's disease of bone with single dose intravenous pamidronate.
OBJECTIVE
To assess the efficacy of a single intravenous infusion of pamidronate in Paget's disease of bone.


METHODS
Fourteen patients with active Paget's disease (raised serum alkaline phosphatase, bone pain or neurological involvement) were treated with a single intravenous infusion of 105 mg pamidronate. Patients were assessed for biochemical and clinical improvement for up to two years following treatment. A further infusion was given following symptomatic relapse (pain at a known site of pagetic involvement).


RESULTS
Serum alkaline phosphatase fell following treatment, with a nadir 5.9 months after treatment. Bone pain was improved in nine of 12 patients after six months. Retreatment of four patients resulted in a similar response.


CONCLUSIONS
Single dose intravenous pamidronate (105 mg) is a convenient and effective treatment for Paget's disease.
Watts
R A
RA
Department of Rheumatology, Addenbrooke's Hospital, Cambridge, United Kingdom.
Skingle
S J
SJ
Bhambhani
M M
MM
Pountain
G
G
Crisp
A J
AJ
D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood; D004164:Diphosphonates / Q000008:administration & dosage* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D010001:Osteitis Deformans / Q000188:drug therapy* / Q000201:enzymology; D000077268:Pamidronate
D004164:Diphosphonates; D000469:Alkaline Phosphatase; D000077268:Pamidronate